IBRX Signs Exclusive U.S. Agreement with Japan BCG Laboratory for Tokyo Strain BCG, Backed by Positive Phase III SWOG S1602 Trial Results
ImmunityBio, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.24
-3.5% in 7d after detection
Post-detection moves
1h
—
1d
-3.0%
3d
-3.3%
7d
-3.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS